Erasca (ERAS) Capital Expenditures (2020 - 2026)
Erasca (ERAS) posted Capital Expenditures of $36000.0 for Q1 2026, up 300.0% on a QoQ basis from $9000.0 in Q4 2025, and down 56.63% year-over-year from $83000.0 in Q1 2025.
Erasca (ERAS) Capital Expenditures (2020 - 2026) Analysis & Trends
Erasca's Capital Expenditures history runs 7 years deep, the most recent figure standing at $36000.0 for Q1 2026.
- Quarterly Capital Expenditures fell 56.63% year-over-year to $36000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81000.0 (down 19.8% YoY) and the FY2025 annual result came in at $128000.0, up 113.33% from the prior year.
- Capital Expenditures was $36000.0 for Q1 2026 at Erasca, up from $9000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $7.3 million in Q1 2022 and bottomed at $5000.0 in Q3 2024.
- A 5-year average of $1.0 million and a median of $82500.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 5913.11% — and 2024, when it slumped 97.92%.
- Erasca's Capital Expenditures stood at $864000.0 in 2022, then plunged by 90.51% to $82000.0 in 2023, then tumbled by 93.9% to $5000.0 in 2024, then surged by 80.0% to $9000.0 in 2025, then soared by 300.0% to $36000.0 in 2026.
- Business Quant data shows ERAS's Capital Expenditures at $36000.0 in Q1 2026, $9000.0 in Q4 2025, and $6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,000.00 |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Sep 30, 2023 | 240,000.00 |
| Sep 30, 2023 | 240,000.00 |